Introduction
Patients and methods
Study design and patient population
Endpoints
Statistical analysis
Results
Baseline characteristics | Patient A | Patient B | Patient C | Patient D | Patient E | Patient F | Patient G | Patient H | Patient I |
---|---|---|---|---|---|---|---|---|---|
Age, years/sex | 45/F | 65/M | 73/F | 41/M | 69/M | 70/F | 61/F | 32/M | 58/M |
Prior HSCT | Yes | No | No | Yes | No | No | Yes | No | Yes |
Histology review | DLBCL | Othera | DLBCL | DLBCL | DLBCL | tMALT lymphoma | DLBCL | DLBCL | DLBCL |
Cell of originb | ABC | NA | ABC | ABC | GCB | ABC | GCB | ABC | ABC |
Previous lines of therapies | 4 | 2 | 3 | 2 | 3 | 5 | 2 | 2 | 3 |
Disease status at the start of the trial | Relapsed | Relapsed | Relapsed | Relapsed | Relapsed | Refractory | Relapsed | Relapsed | Refractory |
Double/triple hits | Negative | NA | Negative | Negative | Negative | Negative | Negative | MYC + BCL6 + rearrangements | NA |
Bridging chemotherapy prior to infusion | Yes | Yes | No | No | Yes | Yes | Yes | Yes | No |
Investigator-assessed overall response prior to infusion | CR | SD | PD | PD | SD | PR | SD | PD | SD |
LDH (U/L) prior to infusionc | 144 | 331 H | 222 | 264 H | 497 H | 202 | 261 H | 510 H | 354 H |
Efficacy
Efficacy and cellular kinetic variables | Patient A | Patient B | Patient C | Patient D | Patient E | Patient F | Patient G | Patient H | Patient I |
---|---|---|---|---|---|---|---|---|---|
Best overall response | CR | PD | CR | PR | PR | CR | CR | PD | CR |
Time to response, days | 28 | – | 28 | 31 | 28 | 30 | 90 | – | 91 |
Duration of response, days | 523+ | – | 51+ | 55 | 52+ | 148+ | 1+ | – | 1+ |
Progression-free survival, days | 550+ | 29 | 78+ | 85 | 79+ | 177+ | 90+ | 36 | 91+ |
Event-free survival, days | 550+ | 29 | 78+ | 85 | 126 | 207 | 90+ | 36 | 91+ |
Overall survival, days | 710+ | 231 | 144+ | 86+ | 183+ | 207+ | 160+ | 45 | 91+ |
AUC0–28d, copies/µg × days | 83,800 | 35,400 | 21,700 | 34,200 | 57,600 | 7290 | 189,000 | 1,740,000 | 2730 |
Cmax, copies/µg | 9410 | 6120 | 2470 | 4420 | 5840 | 846 | 11,900 | 137,000 | 149 |
Tmax, days | 5.82 | 5.85 | 8.78 | 12.9 | 5.73 | 6.96 | 11.0 | 26.7 | 19.8 |
T1/2, days | 408 | 7.53 | 26.6 | 1.18 | 32.4 | 4.16 | 77.9 | 2.72 | - |
Safety
AEs (regardless of study drug relationship) | Patients (N = 9) | ||
---|---|---|---|
All grades, n (%) | Grade 3, n (%) | Grade 4, n (%) | |
Cytokine release syndrome | 6 (66.7) | 2 (22.2) | 0 |
Anemia | 4 (44.4) | 2 (22.2) | 0 |
Decreased neutrophil count | 4 (44.4) | 2 (22.2) | 2 (22.2) |
Decreased white blood cell count | 4 (44.4) | 2 (22.2) | 1 (11.1) |
Decreased lymphocyte count | 3 (33.3) | 1 (11.1) | 2 (22.2) |
Decreased platelet count | 3 (33.3) | 1 (11.1) | 1 (11.1) |
Decreased appetite | 3 (33.3) | 1 (11.1) | 0 |
Patients (N = 9) | |||
---|---|---|---|
All grades, n (%) | Grade 3, n (%) | Grade 4, n (%) | |
Cytokine release syndromea | 6 (66.7) | 1 (11.1) | 1 (11.1) |
Neurological eventsb | 1 (11.1) | 1 (11.1) | 0 |
Cytopenias not resolved by day 28 | 7 (77.8) | 6 (66.7) | 1 (11.1) |
Infections | 4 (44.4) | 0 | 0 |
Tumor lysis syndrome | 1 (11.1) | 0 | 1 (11.1) |
Patients with CRS (N = 6) | |
---|---|
Time to onset, median (range), days | 4.0 (1–8) |
Duration, median (range), days | 7.5 (4–11) |
Oxygen supplementation, n (%) | 3 (50.0) |
Anti-cytokine therapy, n (%) | 2 (33.3) |
Tocilizumab | 2 (33.3) |
Corticosteroids | 0 |
ICU admission, n (%) | 0a |
Hypotension that required intervention, n (%) | 0 |
High-dose vasopressors | 0 |
Intubated, n (%) | 0 |